1Hanauer SB, Feagan BG, Liehtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet ,2002,359 : 1541-1549. 被引量：1
2Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med, 2010,362:1383-1395. 被引量：1
3Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease : the CHARM trial. Gastroenterology, 2007,132 : 52-65. 被引量：1
4D'Haens G, Baert F, van Assehe G, et al. Early combined imnaunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet, 2008,371:660-667. 被引量：1
5Schreiber S, Reiniseh W, Colombel JF, et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis, 2013,7:213-221. 被引量：1
7D'I-Iaens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. Am J Gastroenterol, 2011,106: 199-212. 被引量：1
8Louis E, Vermeire S, Rutgeerts P, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Seand J Gastroenterol, 2002,37:818-824. 被引量：1
